Prostate Cancer

Yonsa (Fine-Particle Abiraterone Acetate) New Formulation Approved for Metastatic Prostate Cancer

2019 Fourth Annual Oncology Guide to New FDA Approvals - FDA Approvals, News & Updates, Prostate Cancer

Prostate cancer is the third most common type of cancer in the United States, after breast cancer and lung cancer. In 2018 alone, 164,690 individuals were diagnosed with prostate cancer, accounting for nearly 10% of all new cancer cases, and 29,430 deaths were attributed to the disease. Prostate cancer is most frequently diagnosed in men aged 65 to 74 years (median age, 66 years). More than 98% of patients with prostate cancer survive ≥5 years; however, the 5-year survival rate drops to 30% for patients with metastatic disease. [ Read More ]

Erleada (Apalutamide) First Drug Approved by the FDA for Nonmetastatic Castration-Resistant Prostate Cancer

Loretta Fala

2019 Fourth Annual Oncology Guide to New FDA Approvals - FDA Approvals, News & Updates, Prostate Cancer

Prostate cancer, the second most common type of cancer in men, is expected to affect 11.6% of all men during their lifetime. In fact, more than 3 million men in the United States are living with prostate cancer. It is estimated that in 2017, 161,360 men were newly diagnosed with prostate cancer, and 26,730 men died from the disease. [ Read More ]

Expert Panel Tackles Merits of End Points in Castrate-Resistant Prostate Cancer: Impact on Treatment and Coverage Decisions

Wayne Kuznar

AVBCC Special Feature, Prostate Cancer

Nearly 12% of American men will be diagnosed with prostate cancer at some point during their lives. Prostate cancer may remain indolent, but it often requires treatment, as evidenced by the more than 26,000 deaths attributable to this disease annually. Although the 5-year survival is high for men with localized prostate cancer, this drops to 29% in men with metastatic prostate cancer. Even with treatment, prostate cancer progresses in more than 33% of men. The median time to metastatic disease is approximately 8 to 10 years after the detection of biochemical recurrence. [ Read More ]

Active Surveillance the Least Costly Management Strategy for Low-Risk Prostate Cancer

Wayne Kuznar

Prostate Cancer, Solid Tumors, Value in Oncology

San Francisco, CA—Active surveillance is less costly than immediate treatment of low-risk prostate cancer, regardless of the specific treatment, according to findings from a cost analysis at a single institution presented at the 2018 Genitourinary Cancers Symposium. The cost-effectiveness of initial active surveillance compared with immediate treatment, as well as mitigation of treatment-related side effects, supports consideration of active surveillance as a management strategy in value-based care models, said lead investigator Franklin Gaylis, MD, FACS, Medical Director, Genesis Healthcare Partners (GHP), San Diego, who presented the study results. [ Read More ]